It is a pleasure to share the new publication on the comprehensive genome-scale map of structural variants in #India from whole #genome sequences authored by @mkdivakar et al. from @SridharSivasub3 Lab at @IGIBSocial#IndiGen
https://t.co/I8a4hebSyy
🆕Here is a First Report on Current #lumpyskindisease Outbreak, In India.
Genetic and Phylogenetic analysis of the LSD Viral Isolate from the Current LSD Outbreak in India Suggest a Distinct Lineage of the Virus.
@vinodscaria@bani_jolly @SridharSivasub3
👇https://t.co/rqMy5jro9s
Join us as Dr @SridharSivasub3 from @IGIBSocial discusses relevance of genomic surveillance of #SARSCoV2 and adapting @illumina COVIDseq test for benchtop sequencers.
Register here: https://t.co/3LFFxQp4av
A recent preprint from our lab is a modification of the @illumina COVIDSeq assay for SARS-CoV-2 genome sequencing, this assay could benefit from optimization for smaller throughput Illumina benchtop types of equipment for smaller batch sizes.
Available at: https://t.co/AVnekoeiE8
Recent preprint in collaboration with clinicians at Govt Medical College Kozhikode, Ernakulam and Idukki and @SridharSivasub3 lab at @IGIBSocial on genomic survey of #SARSCoV2 vaccine breakthrough infections from #Kerala#India
Read the preprint here https://t.co/IE2EubU37S
B.1.618 - a new lineage of SARS-CoV-2 predominnatly found in India and characterized by a distinct set of genetic variants including E484K , a major immune escape variant.
Publication out from @vinodscaria @SridharSivasub3 and CSIR group in India using Illumina COVIDSeq to sequence 200 samples from patients in Kerala region of India. They were able to identify new variants and uncover unique patterns of transmission.
https://t.co/KtBtE2061P
I'm going to disagree. Things don't just work because scientists work hard and show up every day. There is a huge component of luck and timing of convergence of multiple technologies at just the right time. The hard work is necessary but so is the timing/luck (miracle).
For the 1st time, Officially Reviewed 2 research articles.
1st paper got summarily rejected in initial review, potentially due to unrealistic claims with limited data and overlooking other observations.
2nd paper is finally accepted with 2 revisions in 3 months.
#Reviewer
Could anyone please help us by pointing out literature / patent / preprints describing the sequences/structure of spike / inactivated virus(es) used in the #SARSCoV2 vaccines approved / under trials / under development ?
Please 🔁 with anyone who could help.